All products and services featured are independently chosen by editors. However, Flow Space may receive a commission on orders placed through its retail links, and the retailer may receive certain ...

Researchers warned that to achieve such reductions, greater uptake of the medication among indicated patients is needed.

The phase 3b STEP UP trial in more than 1,400 patients compared a 7.2mg weekly subcutaneous injection of semaglutide to the standard 2.6mg weekly dose sold as Wegovy or a matched placebo.

Eli Lilly has met its goal of achieving semaglutide-like efficacy with an ... compared to a 0.1% drop in the placebo group. The result caused the trial to meet its primary endpoint.

Both the injectable and oral forms of semaglutide, a glucagon-like peptide-1 receptor agonist, have gained recent attention for their effectiveness against weight gain, high blood sugar ...

in the oral semaglutide group, as compared with 668 of the 4825 participants (13.8%; incidence, 3.7 events per 100 person-years) in the placebo group (hazard ratio, 0.86; 95% confidence interval ...

In 81.7% of visits, semaglutide was the only medication implicated and was almost always in injectable form (94.0%); medication errors were involved in 9.0% of visits. Emergency department visits ...

Semaglutide, a glucagon-like peptide 1 (GLP-1) agonist, significantly improved maximal walking distance in people with symptomatic peripheral artery disease (PAD) and Type 2 diabetes in the first ...